Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Historical Holders from Q3 2018 to Q3 2025

Symbol
CRNX on Nasdaq
Type / Class
Equity / Common Stock
Shares outstanding
94.2M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
108M
Holdings value
$4.49B
% of all portfolios
0.004%
Grand Portfolio weight change
+0%
Number of holders
222
Number of buys
122
Number of sells
-108
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +46% $466M $144M 14M +44.9% FMR LLC 31 Mar 2025
VANGUARD GROUP INC 10% +2% $311M $7.42M 9.31M +2.44% The Vanguard Group 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 8.9% +45% $349M $107M 8.38M +44.3% Wellington Management Group LLP 30 Sep 2025
Farallon Capital Partners, L.P. 6% $164M 5.63M Dapice Joshua J. 29 Aug 2025

Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock (CRNX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 108M $4.49B +$150M $41.65 222
2025 Q2 105M $3.01B +$75M $28.76 220
2025 Q1 102M $3.42B +$9.86M $33.54 225
2024 Q4 99.7M $5.1B +$758M $51.13 245
2024 Q3 84.5M $4.32B +$33.7M $51.10 233
2024 Q2 82.5M $3.69B +$92.2M $44.79 232
2024 Q1 80.4M $3.76B +$487M $46.81 201
2023 Q4 70.7M $2.51B +$68.3M $35.58 180
2023 Q3 68.5M $2.04B +$441M $29.74 171
2023 Q2 54.1M $974M -$11.8M $18.02 138
2023 Q1 55.1M $884M +$2.28M $16.06 127
2022 Q4 54.8M $1B -$14.3M $18.30 121
2022 Q3 51.5M $1.01B +$16.1M $19.64 118
2022 Q2 50.6M $945M +$94.6M $18.65 109
2022 Q1 45.5M $997M -$15.1M $21.95 114
2021 Q4 44.3M $1.26B +$252M $28.41 114
2021 Q3 33.6M $708M +$17.2M $21.05 91
2021 Q2 32.7M $617M +$42.4M $18.85 81
2021 Q1 30.7M $465M +$5.52M $15.28 78
2020 Q4 30.4M $429M -$4.59M $14.11 84
2020 Q3 30.3M $475M -$19.9M $15.67 70
2020 Q2 31.5M $546M +$189M $17.52 79
2020 Q1 20.7M $304M +$45.4M $14.70 55
2019 Q4 17.5M $440M -$5.48M $25.09 58
2019 Q3 15.2M $229M -$94.3M $15.04 60
2019 Q2 18.9M $473M +$31.1M $25.00 63
2019 Q1 17.7M $404M +$20.7M $22.76 62
2018 Q4 16.8M $503M +$19M $29.99 50
2018 Q3 16.2M $463M +$463M $28.65 49